Eli Lilly reports that its daily GLP-1 weight-loss pill, Foundayo, reduces obstructive sleep apnea in late-stage clinical studies, with trial data indicating improvements in the condition.
Multiple outlets frame the results as an early step toward a potential new treatment option for people with moderate-to-severe sleep apnea who also have obesity or are overweight. Quartz and CNBC both describe regulatory timelines, saying Lilly plans to seek U.S. approval for Foundayo in that patient group. Both reports cite intentions to file with the FDA by 2026, with CNBC specifying an end-of-year filing plan.
STAT also covers the same late-stage trial findings and notes an important comparative angle: Foundayo appears less effective than Lilly’s injectable GLP-1 drug Zepbound, according to the reporting. Across sources, coverage centers on efficacy signals from the trials and the next regulatory steps, with outlets differing mainly in how they emphasize timelines and comparisons to Lilly’s other obesity medication.
